ABVD

ABVD is a combination chemotherapy regimen that was developed in the early 1970's as an alternative to MOPP. ABVD is now one of the most common regimens for treating Hodgkin's Disease.

Drug Names

  • Adriamycin (generic name: Doxorubicin; brand names: Adriamycin PFS, Adriamycin RDF, Rubex)
  • Bleomycin (brand name: Bienoxane
  • Viznblastine (brand names: Velban, Velsar, and Velbe)
  • Dacarbazine (brand names: DTIC, DTIC-Dome)

Drug Administration

The ABVD chemotherapy regimen is usually administered in four-week cycles. The four drugs are administered intravenously on days 1 and 15 of each cycle, with the remaining days left for patient recovery. Dosing differs based on a person’s body mass.

Adriamycin side effects

Adriamycin can cause many side effects, including nausea, alopecia (hair loss), and neutropenia (depletion of white blood cells). It can also cause heart problems, such as arrhythmias, in some patients.

Bleomycin side effects

Bleomycin can cause a fever, rash, alopecia, and Raynaud’s phenomenon (a discoloration of the fingers and/or toes). However, the most serious side effect is the occurrence of pulmonary fibrosis, which impairs the lungs.

Vinblastine side effects

Vinblastine can cause neutropenia, ulcers, blisters, and nausea.

Dacarbazine side effects

Dacarbazine causes severe nausea in some patients, as well as neutropenia, headaches, fatigue, and diarrhea.

Other Side Effects and Common Medications

Chemotherapy can cause frequent urination because of the high amount of fluid entering the body intravenously during treatment. Catheters might be used to allow for stronger doses in some patients. Extra fluids should be consumed during treatment to help prevent kidney damage.

Treatment can also cause constipation; if this occurs, your doctor should prescribe a laxative.

Anti-nausea medicines, such as Zofran or Kytril are usually given during chemotherapy treatments to help with side effects. Pain relievers may also be prescribed.

All chemotherapy agents can cause birth defects in babies conceived or carried during ABVD chemotherapy treatment. There is also a risk of infertility. You may want to discuss your options, such as sperm banking or egg harvesting, with your medical team prior to starting treatment.

Lymphoma Treatment Resources

  • The Zevalin radioimmunotherapy regimen is now approved for certain types of NHL.
  • Follow this link to identify a conveniently located cancer treatment center and begin the process of enrollment.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap